SCHEMBL6399427

SCHEMBL6399427

CC(CC(=O)c1c(O)cc(O)cc1P(=O)(O)O)c1cccc(O)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.35
HDAC4 P56524 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
LMNA P02545 3/20 0.35
HIF1A Q16665 3/20 0.35
KDM4E B2RXH2 2/20 0.35
DRD3 P35462 2/20 0.35
MEN1 O00255 1/20 0.35
CYP3A4 P08684 1/20 0.35
PTGS1 P23219 1/20 0.35
KMT2A Q03164 1/20 0.35
ADRB1 P08588 2/20 0.35
ADRA1A P35348 2/20 0.35
MIF P14174 1/20 0.35
HTR2A P28223 1/20 0.35
HTR2B P41595 1/20 0.35
KYNU Q16719 1/20 0.33
ADRB2 P07550 1/20 0.33
HTR1A P08908 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6401994 0.89 HDAC4 (0.39) FFAR1HDAC4HDAC2HDAC8LMNA
SCHEMBL6404296 0.86 MEN1 (0.38) FFAR1LMNAKDM4EDRD3MEN1
SCHEMBL6395002 0.82 HIF1A (0.36) HDAC4HDAC2HDAC8LMNAHIF1A
SCHEMBL6399420 0.82 LMNA (0.33) FFAR1HDAC4HDAC2HDAC8LMNA
SCHEMBL6396304 0.82 HDAC4 (0.33) FFAR1HDAC4HDAC2HDAC8LMNA
SCHEMBL6396815 0.81 HIF1A (0.37) LMNAHIF1AKDM4EDRD3MEN1
SCHEMBL6394698 0.80 HIF1A (0.36) HDAC4HDAC2HDAC8LMNAHIF1A
SCHEMBL6402288 0.79 HDAC4 (0.38) HDAC4HDAC2HDAC8LMNAHIF1A
SCHEMBL6394416 0.78 LMNA (0.40) HDAC4HDAC2HDAC8LMNAHIF1A
SCHEMBL6401217 0.77 HDAC4 (0.36) HDAC4HDAC2HDAC8LMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 FFAR1 1384/4885HDAC4 3531/4885HDAC2 4401/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 FFAR1 1475/4885HDAC4 3433/4885HDAC2 4287/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 FFAR1 1384/4885HDAC4 3531/4885HDAC2 4401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.